Among the latter class, molecules that impair the formation of the AurkA/TPX2 complex may result in promising tools to disrupt AurkA nuclear functions in cancer, which would instead remain largely untargeted by molecules inhibiting its kinase activity. The gene discussed is TPX2; the disease is cancer.